Whole Body Vibration in Chronic Obstructive Pulmonary Disease

NCT01850173 | Completed

• 1 other identifier: MAT-VIB01
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators designed the current study with the main objective of determining whether Whole Body Vibration Training (WBVT) alone improves muscular force and/or modifies the functional capacity parameters in severe Chronic Obstructive Pulmonary Disease (COPD) patients referred to a rehabilitation programme.

Conditions

COPD

Outcome Measures

Primary Outcomes (2)

• isokinetic knee flexor and extensor testing muscular force

  the change between basal - and 3 months follow up.

  basal, 3 months follow up

• distance performed in the six minutes walking test (6MWT)

  the change between basal - and 3 months follow up.

  Basal, 3 months follow up

Secondary Outcomes (1)

• respiratory muscular strength was assessed with maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)

  Basal, 3 month follow up

Other Outcomes (1)

• Complications

  3 months follow up

Study Arms (2)

static work with a vertical vibration platform

EXPERIMENTAL

The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.

Device: A vertical vibration platform Fitybe

Control group

NO INTERVENTION

general recommendations about physical activity and lifestyle

Interventions

A vertical vibration platform Fitybe DEVICE

They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.

static work with a vertical vibration platform

Eligibility Criteria

• Age: 55 Years - 85 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• severe COPD defined as a post-bronchodilator forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) \< 0.7 and FEV1 \< 50% predicted,
• stable disease defined as no exacerbation,
• hospital admission or change in treatment in the previous 3 months.

You may not qualify if:

• other significant respiratory disease (bronchiectasis,
• lung fibrosis, asthma, etc),
• active smoking,
• severe cardiovascular,
• neurological, and/or metabolic pathology that could interfere with the results,
• total hip, knee or ankle arthroplasty,
• previous vitreous haemorrhage,
• severe alcoholism (\> 80 g/day) and
• severe malnutrition (BMI \< 19 Kg/m2) to reduce the risk of falling and dropouts.

Sponsors & Collaborators

• Hospital de Mataró: lead

Study Sites (1)

Eulogio Pleguezuelos

Mataró, Barcelona, 08304, Spain

Location

Related Links

• Hospital de Mataró. Consorci Sanitari del Maresme

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Eulogio Pleguezuelos, PhD

  Hospital de Mataró

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: May 2, 2013
• First Posted: May 9, 2013
• Study Start: February 1, 2010
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: May 9, 2013

Record last verified: 2013-05

Locations

ES (1)